(NASDAQ: CERE) Cerevel Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cerevel Therapeutics Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CERE's revenue for 2025 to be $2,454,914,037, with the lowest CERE revenue forecast at $2,454,914,037, and the highest CERE revenue forecast at $2,454,914,037. On average, 7 Wall Street analysts forecast CERE's revenue for 2026 to be $21,045,077,417, with the lowest CERE revenue forecast at $3,540,741,399, and the highest CERE revenue forecast at $55,061,252,402.
In 2027, CERE is forecast to generate $82,680,306,349 in revenue, with the lowest revenue forecast at $17,104,504,604 and the highest revenue forecast at $216,747,846,563.